BACKGROUND: Abnormalities of fibroblast growth factor-23 (FGF-23) plasma levels predict adverse outcomes in patients with coronary artery disease. However, FGF-23 has a different behaviour in the presence of type 2 diabetes mellitus (T2D). We explored whether the presence of T2D affects the predictive power of FGF-23. METHODS: In 704 patients with stable coronary artery disease, FGF-23, calcidiol, parathormone (PTH) and phosphate plasma levels were prospectively assessed. The primary outcome was the development of acute ischemic events (acute coronary syndrome, stroke or transient ischemic attack), heart failure or death. RESULTS: One hundred seventy-three (24.6%) patients had T2D, without differences in age, sex or estimated glomerular filtration rate as compared with non-diabetic patients. Serum PTH was lower and phosphate higher in T2D than in non-diabetic patients, without differences in FGF-23 or calcidiol levels. During follow-up (2.15 ± 0.99 years), 26 (15.2%) T2D and 51 (9.6%) non-diabetic patients developed the outcome (p = 0.048). T2D patients who developed the outcome had higher FGF-23 [112.0 (59.9, 167.6) vs 68.9 (54.2, 93.0) RU/mL; p = 0.002], PTH [71.3 (47.3, 106.6) vs 51.9 (40.8, 66.2) pg/mL; p = 0.004) and phosphate (3.53 ± 0.71 vs 3.25 ± 0.50 mg/dL; p = 0.017) levels than T2D subjects who remained stable. These differences were not significant in non-diabetic patients. By multivariable Cox proportional hazard model, FGF-23 predicted independently the outcome in T2D patients [hazard ratio = 1.277; 95% CI (1.132, 1.442)] but not in those without T2D. CONCLUSIONS: FGF-23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients who have T2D but not in those without T2D. This finding should be confirmed in larger studies.
BACKGROUND: Abnormalities of fibroblast growth factor-23 (FGF-23) plasma levels predict adverse outcomes in patients with coronary artery disease. However, FGF-23 has a different behaviour in the presence of type 2 diabetes mellitus (T2D). We explored whether the presence of T2D affects the predictive power of FGF-23. METHODS: In 704 patients with stable coronary artery disease, FGF-23, calcidiol, parathormone (PTH) and phosphate plasma levels were prospectively assessed. The primary outcome was the development of acute ischemic events (acute coronary syndrome, stroke or transient ischemic attack), heart failure or death. RESULTS: One hundred seventy-three (24.6%) patients had T2D, without differences in age, sex or estimated glomerular filtration rate as compared with non-diabeticpatients. Serum PTH was lower and phosphate higher in T2D than in non-diabeticpatients, without differences in FGF-23 or calcidiol levels. During follow-up (2.15 ± 0.99 years), 26 (15.2%) T2D and 51 (9.6%) non-diabeticpatients developed the outcome (p = 0.048). T2D patients who developed the outcome had higher FGF-23 [112.0 (59.9, 167.6) vs 68.9 (54.2, 93.0) RU/mL; p = 0.002], PTH [71.3 (47.3, 106.6) vs 51.9 (40.8, 66.2) pg/mL; p = 0.004) and phosphate (3.53 ± 0.71 vs 3.25 ± 0.50 mg/dL; p = 0.017) levels than T2D subjects who remained stable. These differences were not significant in non-diabeticpatients. By multivariable Cox proportional hazard model, FGF-23 predicted independently the outcome in T2D patients [hazard ratio = 1.277; 95% CI (1.132, 1.442)] but not in those without T2D. CONCLUSIONS:FGF-23 plasma levels predict adverse cardiovascular outcomes in coronary artery diseasepatients who have T2D but not in those without T2D. This finding should be confirmed in larger studies.
Authors: Brian A Bergmark; Jacob A Udell; David A Morrow; Christopher P Cannon; Dylan L Steen; Petr Jarolim; Andrzej Budaj; Christian Hamm; Jianping Guo; KyungAh Im; Julia F Kuder; Eugene Braunwald; Marc S Sabatine; Michelle L O'Donoghue Journal: JAMA Cardiol Date: 2018-06-01 Impact factor: 14.676
Authors: Christoph Nowak; Axel C Carlsson; Carl Johan Östgren; Fredrik H Nyström; Moudud Alam; Tobias Feldreich; Johan Sundström; Juan-Jesus Carrero; Jerzy Leppert; Pär Hedberg; Egil Henriksen; Antonio C Cordeiro; Vilmantas Giedraitis; Lars Lind; Erik Ingelsson; Tove Fall; Johan Ärnlöv Journal: Diabetologia Date: 2018-05-24 Impact factor: 10.122
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112
Authors: Marie Frimodt-Møller; Bernt Johan von Scholten; Henrik Reinhard; Peter Karl Jacobsen; Tine Willum Hansen; Frederik Ivar Persson; Hans-Henrik Parving; Peter Rossing Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240
Authors: A Lorenzo-Almorós; A Pello; Á Aceña; J Martínez-Milla; Ó González-Lorenzo; N Tarín; C Cristóbal; L M Blanco-Colio; J L Martín-Ventura; A Huelmos; C Gutiérrez-Landaluce; M López-Castillo; A Kallmeyer; E Cánovas; J Alonso; L López Bescós; J Egido; Ó Lorenzo; J Tuñón Journal: J Clin Med Date: 2020-04-13 Impact factor: 4.241